Meet us at ISPOR 2023

Pass by our booth (number C3-079) to discuss your projects or visit our poster (EPH86) during the Poster Session 2 on Monday the 13th between 4-5PM to know more on how the approval of a new medicine shapes the evolution of epidemiology in rare diseases.

Meet our VP at BioFuture

BioFuture is where relentless therapeutic pioneers, innovators, and investors gather to assess and shape the future of healthcare and digital health.

 Our VP, Ted Haack, will attend BioFuture and is looking forward to discussing with you !

Meet us at Fierce Biotech New Product Planning Summit

The Fierce New Product Planning Summit is the ONLY conference dedicated to defining how the new product planning role and related functions make informed, value-based, data-driven decisions about products in the pipeline. Life science industry professionals gather here each year to consider how and when to utilize various resources and ask the right questions to ensure commercial success.

Sean Robbins, our managing partner, and Karin Steinbach, our Director of Market Access, Pricing and Reimbursement Strategy, will present a session titled “Future-Proofing Your Product Planning with an Objective Framework“.

Demy-Colton 2023

Sara Demy, CEO of Demy-Colton, hosts interactive virtual salons featuring industry leaders and distinguished guests exploring today’s most consequential and disruptive topics in healthcare.

Market Access and Valuation: Key Considerations for Multi-Indication Products: The discussion focused on the issues that potential commercialization partners, acquirers and capital providers will examine when evaluating a multi-indication product as well as platform products for deal valuation purposes. This panel of experts shared their experiences as CEOs, BD and Market Access leaders, Country Managers and royalty investors from companies including Alexion, DRI Capital, Genentech, Genzyme, GSK, and Pfizer.

Demy-Colton 2021

Sara Demy, CEO of Demy-Colton, hosts interactive virtual salons featuring industry leaders and distinguished guests exploring today’s most consequential and disruptive topics in healthcare.

Strategic Pricing: Optimizing product valuation by avoiding bias and thinking locally
Price is one of the three key variables in the profit function, a critical negotiation point prior to patient access, and a component of the industry’s image issue. Companies can overestimate price due to internal biases, use of inappropriate analogues, avoidance of in-country details and the focus on regulatory endpoints at the expense of payer-relevant endpoints. Indeed, fast to label is not necessarily fast to patient access. Given the dominant role price plays in enterprise valuation, the panel today will discuss the key pricing issues, including optimism bias, ways to mitigate these risks and why payer research isn’t always the best answer. Participants will leave with a better understanding of how to optimize pricing and access estimates and improve the quality of engagement with investors, stakeholders and partners as a result.